These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 16386826)
1. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Yasui-Furukori N; Saito M; Nakagami T; Kaneda A; Tateishi T; Kaneko S Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):286-91. PubMed ID: 16386826 [TBL] [Abstract][Full Text] [Related]
2. MDR1 gene polymorphisms and response to acute risperidone treatment. Kastelic M; Koprivsek J; Plesnicar BK; Serretti A; Mandelli L; Locatelli I; Grabnar I; Dolzan V Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):387-92. PubMed ID: 20060871 [TBL] [Abstract][Full Text] [Related]
3. Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Yasui-Furukori N; Tsuchimine S; Saito M; Nakagami T; Sato Y; Kaneko S Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1230-4. PubMed ID: 17559997 [TBL] [Abstract][Full Text] [Related]
4. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia. Sakumoto N; Kondo T; Mihara K; Suzuki A; Yasui-Furukori N Psychiatry Clin Neurosci; 2007 Apr; 61(2):174-80. PubMed ID: 17362435 [TBL] [Abstract][Full Text] [Related]
5. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients. Lee HY; Kim DJ; Lee HJ; Choi JE; Kim YK Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):276-80. PubMed ID: 19059448 [TBL] [Abstract][Full Text] [Related]
6. Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients. Kondo T; Mihara K; Suzuki A; Yasui-Furukori N; Kaneko S Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):921-6. PubMed ID: 14499308 [TBL] [Abstract][Full Text] [Related]
7. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Sills GJ; Mohanraj R; Butler E; McCrindle S; Collier L; Wilson EA; Brodie MJ Epilepsia; 2005 May; 46(5):643-7. PubMed ID: 15857428 [TBL] [Abstract][Full Text] [Related]
8. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Yi SY; Hong KS; Lim HS; Chung JY; Oh DS; Kim JR; Jung HR; Cho JY; Yu KS; Jang IJ; Shin SG Clin Pharmacol Ther; 2004 Nov; 76(5):418-27. PubMed ID: 15536457 [TBL] [Abstract][Full Text] [Related]
9. MDR1 gene polymorphisms and risk of gingival hyperplasia induced by calcium antagonists. Meisel P; Giebel J; Kunert-Keil C; Dazert P; Kroemer HK; Kocher T Clin Pharmacol Ther; 2006 Jan; 79(1):62-71. PubMed ID: 16413242 [TBL] [Abstract][Full Text] [Related]
10. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Wu S; Xing Q; Gao R; Li X; Gu N; Feng G; He L Neurosci Lett; 2005 Mar; 376(1):1-4. PubMed ID: 15694263 [TBL] [Abstract][Full Text] [Related]
11. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Pauli-Magnus C; Feiner J; Brett C; Lin E; Kroetz DL Clin Pharmacol Ther; 2003 Nov; 74(5):487-98. PubMed ID: 14586389 [TBL] [Abstract][Full Text] [Related]
12. Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Owen A; Goldring C; Morgan P; Chadwick D; Park BK; Pirmohamed M Br J Clin Pharmacol; 2005 Mar; 59(3):365-70. PubMed ID: 15752383 [TBL] [Abstract][Full Text] [Related]
13. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Yasui-Furukori N; Mihara K; Takahata T; Suzuki A; Nakagami T; De Vries R; Tateishi T; Kondo T; Kaneko S Br J Clin Pharmacol; 2004 May; 57(5):569-75. PubMed ID: 15089809 [TBL] [Abstract][Full Text] [Related]
14. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584 [TBL] [Abstract][Full Text] [Related]